Drug Trial Radar · NCT07452510
Comparison of Dry Needling and Two Botulinum Toxins for Bruxism
Last checked: Nov 20, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Jan 9, 2026
Primary completion
Apr 8, 2026
Study completion Apr 8, 2026
Sponsor
- Lead sponsor
- Recep Tayyip Erdogan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 5, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
1. Aim: The aim of this study is to prospectively compare the clinical efficacy of Dry Needling (DN), Nabota (PrabotulinumtoxinA), and Dysport (AbobotulinumtoxinA) treatments on the thickness of masseter and anterior temporal muscles and pain intensity (VAS) in patients diagnosed with chronic bruxism. 2. Material and Method: This randomized, prospective, and single-blind clinical study will be conducted on 60 patients diagnosed with bruxism. Patients will be divided into three groups: Dry Needling (n=20), Nabota (n=20), and Dysport (n=20). Pain levels will be assessed using the Visual Analog Scale (VAS) at baseline, 1st month, and 3rd month. Muscle thicknesses will be measured using ultrasonography (USG) at baseline and 3rd month. Data distribution will be analyzed using the Kolmogorov-Smirnov test; intergroup comparisons will be performed using ANOVA and Post-hoc Duncan tests. 3. Results:The results will be analyzed following the completion of the 3-month follow-up period
Conditions
- Bruxism
- Sleep Bruxism, Adult
- Awake Bruxism
- Masseter Muscle Hypertrophy
- Temporomandibular Disorders
Interventions
Dry Needling (DN)Procedure
Deep dry needling application to the masseter and anterior temporal muscles. The procedure was performed in 3 sessions with one-week intervals.
PrabotulinumtoxinADrug
Injection of PrabotulinumtoxinA. A total of 50 Units was administered: 15 Units per masseter muscle and 10 Units per anterior temporal muscle, injected bilaterally in a single session.
AbobotulinumtoxinaDrug
Injection of AbobotulinumtoxinA. A total of 500 Units (reconstituted to approximately 167 Units for equivalence) was administered: 50 Units per masseter muscle and 33.3 Units per anterior temporal muscle, injected bilaterally in a single session.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain Intensity Measured by Visual Analog Scale (VAS)Time frame: Baseline, 1 month, and 3 months.
- Masseter and Anterior Temporal Muscle Thickness Via Ultrasonography (USG)Time frame: 3rd month post-treatment.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Recep Tayyip Erdogan university
Rize, Center, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.